Antimicrobial

CorMedix Inc. to Participate in Two Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

2 years ago

CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath

BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

2 years ago

Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations

Executive function to oversee Edmonton site technical operations with implementation of Pilot Unit for Pressurized Gas eXpanded (PGX) Technology as…

2 years ago

MI4, Montreal’s powerhouse of infectious disease research, celebrates five years of innovation and philanthropy

Vincent Chiara, real estate entrepreneur and founder and President of Groupe Mach donates $1.4 million to the MUCH Foundation for…

2 years ago

ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee

YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…

2 years ago

T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference

LEXINGTON, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens…

2 years ago

CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates

BERKELEY HEIGHTS, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

2 years ago

ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens

YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…

2 years ago

Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel

ProgenaCare to commercialize coactiv+™ Antimicrobial Wound Gel in the U.S. wound care marketWINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) --…

2 years ago

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

- Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious…

2 years ago